NEOMED Institute

Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734

Filippo Spriano, Eugenio Gaudio, Luciano Cascione et al. · Blood Advances · 2020 · 70 citations · Full text

NEO6860, modality-selective TRPV1 antagonist: a randomized, controlled, proof-of-concept trial in patients with osteoarthritis knee pain

Pierre Arsenault, D. Chiche, W. A. Brown et al. · PAIN Reports · 2018 · 61 citations · Full text

Safety, Pharmacokinetics, and Pharmacodynamics Study in Healthy Subjects of Oral NEO6860, a Modality Selective Transient Receptor Potential Vanilloid Subtype 1 Antagonist

W. A. Brown, Richard L. Leff, Andrew M. Griffin et al. · Journal of Pain · 2017 · 48 citations

Oral Neo6860, Healthy Subjects, Pharmacodynamics Study +6

Methylglycol chitosan and a synthetic TLR4 agonist enhance immune responses to influenza vaccine administered sublingually

Justin L. Spinner, Hardeep S. Oberoi, Yvonne M. Yorgensen et al. · Vaccine · 2015 · 26 citations

Vaccination, Mucosal Vaccination, Cross-protection +9

NEO2734: A novel potent oral dual BET and P300/CBP inhibitor

Francis J. Giles, Michael Witcher, B. Brown · Annals of Oncology · 2018 · 12 citations · Full text